摘要
目的探讨复合乳酸菌联合三联及四联疗法根治幽门螺杆菌(H.pylori)的疗效。方法选取具有上消化道症状且H.pylori阳性患者600例,随机分为四组:三联疗法组(A1)、三联疗法+复合乳酸菌组(A2)、四联疗法组(B1)、四联疗法+复合乳酸菌组(B2),每组150例。三联疗法:雷贝拉唑20 mg+克拉霉素0.5 g+阿莫西林1.0 g,四联疗法:三联疗法+枸橼酸铋钾600 mg。疗程均为14 d。比较四组H.pylori根除率和不良反应发生率。结果 A1、A2、B1、B2组根除率分别为64.0%、78.0%、86.7%、95.3%,不良反应发生率分别为26.0%、14.0%、25.3%、12.7%。复合乳酸菌联合三联、四联组根除率分别比单纯三联、四联组增高,不良反应发生率分别比单纯三联、四联疗法低,且复合乳酸菌联合三联疗法根治H.pylori不良反应发生率低于四联疗法,差异均具有统计学意义(P<0.05)。结论复合乳酸菌联合三联及四联疗法根治幽门螺杆菌可提高H.pylori根除率及减少不良反应。
Objective To explore the efficacy of composite lactobacillus combined with triple or quadruple therapy in eradicating Helicobacter pylori（H. pylori）. Methods 600 cases of H. pylori positive patients with upper digestive tract symptoms were randomly divided into four groups： group A1（received triple therapy）, group A2（received triple therapy ＋ composite lactobacillus）, group B1（received quadruple therapy）, group B2（received quadruple therapy ＋ composite lactobacillus）. Triple therapy： Rabeprazole（20 mg） ＋ CLA（0.5 g） ＋Amoxicillin（1.0 g）, quadruple therapy was given bismuth subcitrate potassium（600 mg） on the basis of triple therapy. The treatment period was 14 days. The eradication rate of H. pylori and adverse reactions rate of four groups were compared. Results The eradication rate of group A1, A2, B1 and B2 were 64.0%, 78.0%, 86.7%, 95.3% respectively, the incidence of adverse reactions were 26.0%, 14.0%, 25.3%,12.7% respectively. The eradication rate of group A2 and group B2 were higher than those of group A1 and group B1, the incidence of adverse reactions of group A2 and B2 were lower than those of group A1 and B1, and the incidence of adverse reactions of group A2 was lower than that of group B1, all the difference was statistical（P〈0.05）. Conclusions Composite lactobacillus combined with triple therapy or quadruple therapy can improve the eradication rate and reduce the adverse reactions in eradicating H. pylori.
出处
《临床医学工程》
2015年第8期1054-1055,共2页
Clinical Medicine & Engineering
关键词
幽门螺杆菌
益生菌
复合乳酸菌
Helicobacter pylori
Probiotics
Composite lactobacillus
